512529 Stock Overview
Operates in the veterinary healthcare business in Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Sequent Scientific Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹195.15 |
| 52 Week High | ₹240.90 |
| 52 Week Low | ₹91.85 |
| Beta | 0.82 |
| 11 Month Change | 1.53% |
| 3 Month Change | 17.67% |
| 1 Year Change | 79.99% |
| 33 Year Change | 9.05% |
| 5 Year Change | 184.27% |
| Change since IPO | 1,723.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| 512529 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -3.8% | -3.1% | -3.4% |
| 1Y | 80.0% | 41.1% | 27.0% |
Return vs Industry: 512529 exceeded the Indian Pharmaceuticals industry which returned 41.1% over the past year.
Return vs Market: 512529 exceeded the Indian Market which returned 27% over the past year.
Price Volatility
| 512529 volatility | |
|---|---|
| 512529 Average Weekly Movement | 8.3% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 512529's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 512529's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 1,195 | Rajaram Narayanan | www.sequent.in |
Sequent Scientific Limited operates in the veterinary healthcare business in Europe, Asia, and internationally. The company provides animal health active pharmaceutical ingredients (APIs) formulations in the areas of anthelmintics, including endo and ecto parasiticides; and anti-protozoal, nutraceuticals, nonsteroidal anti-inflammatory drugs, anti-infectives, and dermatology. It also offers analytical solutions that support API, pharmaceutical, personal care, and nutraceutical organizations; and method validation, stability, and microbiology for APIs and finished products.
Sequent Scientific Limited Fundamentals Summary
| 512529 fundamental statistics | |
|---|---|
| Market cap | ₹48.66b |
| Earnings (TTM) | ₹164.81m |
| Revenue (TTM) | ₹14.54b |
295.3x
P/E Ratio3.3x
P/S RatioIs 512529 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 512529 income statement (TTM) | |
|---|---|
| Revenue | ₹14.54b |
| Cost of Revenue | ₹8.10b |
| Gross Profit | ₹6.44b |
| Other Expenses | ₹6.27b |
| Earnings | ₹164.81m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 44.28% |
| Net Profit Margin | 1.13% |
| Debt/Equity Ratio | 60.9% |
How did 512529 perform over the long term?
See historical performance and comparison